The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis

Heping Xu*, Caijiao Yi, Mei Chen*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

22 Downloads (Pure)

Abstract

Neovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no medication to prevent or treat the condition. Here, we discussed recent advances in the pathogenesis of nAMD-mediated macular fibrosis, with a focus on the role of the complement system. We further proposed approaches to target the complement system for the management of macular fibrosis and highlighted the area of further research for future clinical applications of complement-based therapy.

Original languageEnglish
Article number102448
Number of pages8
JournalCurrent Opinion in Pharmacology
Volume76
Early online date30 Mar 2024
DOIs
Publication statusPublished - Jun 2024

Fingerprint

Dive into the research topics of 'The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis'. Together they form a unique fingerprint.

Cite this